Asset Details
Do you wish to reserve the book?
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
Do you wish to request the book?
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h
2025
Overview
Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized multiple myeloma treatment (MM). However, managing its immune-mediated adverse events, particularly macrophage activation syndrome-
(MAS-
), remains challenging due to underreporting.
This multicentre, retrospective, analytical study evaluated MM patients treated with the anti-BCMA academic product ARI0002h. MAS-
was defined using the University of California San Francisco (UCSF) consensus criteria. Primary endpoints included baseline characteristics, predictive factors, and survival outcomes associated with MAS-
.
Of 80 patients, 12 (15%) met the UCSF criteria for MAS-
. These patients presented higher ISS scores (ISS III: 54.5% vs. 15.2%;
= 0.006), elevated serum monoclonal components (31.3 g/L vs. 6.8 g/L;
= 0.004), and a higher prevalence of extramedullary disease (41.7% vs. 16.2%;
= 0.057). MAS-
typically emerged 9 days post-infusion, with elevated ferritin, followed by LDH (median 11.5 days) and hypofibrinogenemia (median 14 days). One-third of patients met all UCSF criteria, and all exhibited hypertriglyceridemia, hypertransaminasemia, and cytopenias. Histopathological examination was positive in 63% of evaluated patients. Patients who developed MAS-
had poorer responses (CR: 25% vs. 68%; p = 0.008) and shorter median PFS and OS (7 months vs. 21.4 months and 18 months vs. not reached, respectively; p = 0.004). Those meeting all UCSF criteria had even inferior outcomes.
MAS-
is associated with poorer responses, reduced PFS and OS, especially in patients meeting all UCSF criteria. High tumour burden, including elevated monoclonal component, high ISS and extramedullary disease, seems to contribute to MAS-
development.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Aged
/ B-Cell Maturation Antigen - antagonists & inhibitors
/ B-Cell Maturation Antigen - immunology
/ Female
/ Ferritin
/ Humans
/ IEC-HS
/ Immunotherapy, Adoptive - adverse effects
/ Immunotherapy, Adoptive - methods
/ Lymphoma
/ Macrophage Activation Syndrome - diagnosis
/ Macrophage Activation Syndrome - etiology
/ Macrophage Activation Syndrome - immunology
/ Male
/ Multiple Myeloma - immunology
/ Multiple Myeloma - mortality
/ myeloma
/ Patients
/ Receptors, Chimeric Antigen - immunology
/ Toxicity
